Spectrum Pharmaceuticals

Spectrum Pharmaceuticals EBITDA

Delisted

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Spectrum Pharmaceuticals (SPPI) as of Nov 15, 2026 is -72.70 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -147.70 M USD — a change of -50.78% (higher).

EBITDA

-72.70 MUSD

YoY

-50.78%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Spectrum Pharmaceuticals is 2022 -72.70 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Spectrum Pharmaceuticals was 2021 -147.70 M USD. It decreases by -50.78% higher compared to the previous year.

The Spectrum Pharmaceuticals EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2015
-2.43 M USD
Jan 1, 2016
-35.49 M USD
Jan 1, 2017
-96.66 M USD
Jan 1, 2018
-131.18 M USD
Jan 1, 2019
-144.03 M USD
Jan 1, 2020
-169.73 M USD
Jan 1, 2021
-147.70 M USD
Jan 1, 2022
-72.70 M USD
The Spectrum Pharmaceuticals EBITDA history
YEAREBITDAYoY
-72.70 MUSD-50.78%
-147.70 MUSD-12.98%
-169.73 MUSD+17.84%
-144.03 MUSD+9.80%
-131.18 MUSD+35.71%
-96.66 MUSD+172.36%
-35.49 MUSD+1,359.29%
-2.43 MUSD-66.54%
-7.27 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Spectrum Pharmaceuticals Stock analysis

What does Spectrum Pharmaceuticals do? Spectrum Pharmaceuticals Inc. is an American biotechnology company specializing in the development and commercialization of drugs for the treatment of cancer and other serious diseases. It was founded in 1987 and is headquartered in Irvine, California. The company's CEO is Rajesh C. Shrotriya, who has a clear vision of specializing in pharmaceutical development to meet the needs of patients with unmet medical needs. Spectrum Pharmaceuticals has a wide range of products, with a focus on oncology and hematology. It also has a promising drug candidate pipeline. The company works closely with healthcare professionals and regulatory authorities to ensure the highest quality standards are met. Spectrum Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Spectrum Pharmaceuticals stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Spectrum Pharmaceuticals is -72.70 M USD in 2022.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Spectrum Pharmaceuticals changed from -147.70 M USD to -72.70 M USD, representing a -50.78% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Spectrum Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Spectrum Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Spectrum Pharmaceuticals

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Spectrum Pharmaceuticals